CN101277934A - 使代谢型谷氨酸-受体-增效的异吲哚酮 - Google Patents

使代谢型谷氨酸-受体-增效的异吲哚酮 Download PDF

Info

Publication number
CN101277934A
CN101277934A CNA2006800363117A CN200680036311A CN101277934A CN 101277934 A CN101277934 A CN 101277934A CN A2006800363117 A CNA2006800363117 A CN A2006800363117A CN 200680036311 A CN200680036311 A CN 200680036311A CN 101277934 A CN101277934 A CN 101277934A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
alkylaryl
haloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800363117A
Other languages
English (en)
Chinese (zh)
Inventor
B·范瓦格宁
R·乌基马潘迪安
J·克莱顿
I·伊格尔
J·埃姆普费尔德
M·伊萨克
马縛鹏
A·斯拉西
G·斯蒂尔曼
R·乌尔班尼克
S·沃额什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/028760 external-priority patent/WO2006020879A1/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101277934A publication Critical patent/CN101277934A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CNA2006800363117A 2005-08-12 2006-02-15 使代谢型谷氨酸-受体-增效的异吲哚酮 Pending CN101277934A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2005/028760 WO2006020879A1 (en) 2004-08-13 2005-08-12 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
USPCT/US2005/028760 2005-08-12

Publications (1)

Publication Number Publication Date
CN101277934A true CN101277934A (zh) 2008-10-01

Family

ID=36464390

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006800363117A Pending CN101277934A (zh) 2005-08-12 2006-02-15 使代谢型谷氨酸-受体-增效的异吲哚酮
CNA2006800353774A Pending CN101309905A (zh) 2005-08-12 2006-02-15 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2006800353774A Pending CN101309905A (zh) 2005-08-12 2006-02-15 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途

Country Status (4)

Country Link
EP (2) EP1912940A1 (https=)
JP (2) JP5031745B2 (https=)
CN (2) CN101277934A (https=)
WO (2) WO2007021308A1 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US20080139846A1 (en) * 2006-09-01 2008-06-12 Astrazeneca Ab New Process 298
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2008130853A1 (en) * 2007-04-17 2008-10-30 Astrazeneca Ab Hydrazides and their use as metabotropic glutamate receptor potentiators - 681
WO2008131439A1 (en) * 2007-04-23 2008-10-30 House Ear Institute Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7
EP2167464B1 (en) 2007-05-25 2014-12-03 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
WO2009004430A1 (en) * 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
EP2406248B1 (en) * 2009-03-11 2013-12-25 Msd K.K. Novel isoindolin-1-one derivative
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2451350T3 (es) * 2009-10-09 2014-03-26 Celgene Corporation Procedimientos para la preparación de compuestos de 2-(1-feniletil)isoindolin-1-ona
EP2496569A2 (en) 2009-11-02 2012-09-12 MSD Oss B.V. Heterocyclic derivatives
US20130203995A1 (en) * 2010-01-07 2013-08-08 Astrazeneca Ab Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874
US8664214B2 (en) 2010-03-30 2014-03-04 AbbVie Deutschland GmbH & Co. KG Small molecule potentiators of metabotropic glutamate receptors I
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2013056015A1 (en) 2011-10-14 2013-04-18 Incyte Corporation Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
US9586964B2 (en) * 2011-10-28 2017-03-07 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
BR112018008711A2 (pt) 2015-10-29 2018-10-30 Effector Therapeutics Inc compostos de pirrolo-, pirazolo-, imidazo-pirimidina e piridina que inibem mnk1 e mnk2
US10112955B2 (en) 2015-10-29 2018-10-30 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
CN105837557A (zh) * 2016-05-05 2016-08-10 青岛辰达生物科技有限公司 一种用于治疗ii型糖尿病的阿格列汀的制备方法
CN106279182B (zh) * 2016-07-29 2019-06-07 中国药科大学 一种吡咯并[2，1-a]异吲哚酮类化合物及其合成方法
CA3053493A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP3459939A1 (en) * 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
CN113286592A (zh) 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
CN110498759A (zh) * 2019-09-12 2019-11-26 天津瑞岭化工有限公司 异吲哚啉酮类化合物的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE620654C (de) * 1933-04-29 1935-10-24 Smith & Sons Ltd S Geschwindigkeitsanzeiger
US3579524A (en) * 1968-06-05 1971-05-18 Miles Lab 2-aminoalkyl derivatives of phthalimidines
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
DE3717561A1 (de) * 1987-05-25 1988-12-08 Thomae Gmbh Dr K Indol-, isochinolin- und benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH02184667A (ja) * 1989-01-11 1990-07-19 Meiji Seika Kaisha Ltd Ｎ，ｎ’―ジ置換ピペラジル誘導体及びそれを有効成分とする排尿障害改善剤
TW219935B (https=) * 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
CN1158264C (zh) * 1997-11-21 2004-07-21 Nps药物有限公司 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂
US7166617B2 (en) * 2000-02-29 2007-01-23 Mitsubishi Pharma Corporation Cyclic amide derivatives
DE10031391A1 (de) * 2000-07-03 2002-02-07 Knoll Ag Bicyclische Verbindungen und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
ES2291329T3 (es) * 2000-07-18 2008-03-01 Dainippon Sumitomo Pharma Co., Ltd. Inhibidores de la recaptacion de serotonina.
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
CA2542220A1 (en) * 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
US20080275062A1 (en) * 2004-01-30 2008-11-06 David Harold Drewry Chemical Compounds
AU2005219788B2 (en) * 2004-03-05 2010-06-03 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and noxious organism control agent
CN1934094A (zh) * 2004-03-05 2007-03-21 万有制药株式会社 二芳基取代杂环5元环衍生物
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators

Also Published As

Publication number Publication date
CN101309905A (zh) 2008-11-19
WO2007021309A1 (en) 2007-02-22
JP5031745B2 (ja) 2012-09-26
EP1912939A1 (en) 2008-04-23
JP2009509920A (ja) 2009-03-12
JP2009509921A (ja) 2009-03-12
WO2007021308A1 (en) 2007-02-22
EP1912940A1 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
CN101277934A (zh) 使代谢型谷氨酸-受体-增效的异吲哚酮
TWI417100B (zh) 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
US8153638B2 (en) Metabotropic glutamate-receptor-potentiating isoindolones
JP5031565B2 (ja) イソインドール化合物および代謝共役型グルタミン酸受容体増強剤としてのそれらの使用
DE60314639T2 (de) Fusionierte heteroaryl-derivate zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
JP5408434B2 (ja) アミド化合物
WO2008130853A1 (en) Hydrazides and their use as metabotropic glutamate receptor potentiators - 681
CN101605792A (zh) 氮杂-异吲哚酮和它们作为亲代谢性谷氨酸受体增效剂-613的用途
US20110166155A1 (en) Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators
JP4857128B2 (ja) 新規な化合物
CN101511802A (zh) 螺唑烷酮化合物及其作为代谢型谷氨酸受体增效剂的用途
JP2010520876A (ja) ピペラジンおよびピペリジンｍＧｌｕＲ５増強剤
MX2010012357A (es) Compuesto de amida.
CN101268077A (zh) 三环苯并咪唑及其作为代谢型谷氨酸受体调节剂的用途
CN101815512A (zh) 环丙基芳基酰胺衍生物和其用途
CN101679402A (zh) 亲代谢性谷氨酸受体噁二唑配体及其作为增效剂841的用途
JP2009519929A (ja) オキサゾリジノン化合物及び代謝型グルタミン酸レセプター増強剤としてのそれらの使用
WO2012036278A1 (ja) グリシントランスポーター阻害物質
KR20160071408A (ko) 황 함유 이환식 화합물
JP2008532969A (ja) グリシントランスポーター阻害薬としてのアシル化ピペリジン
TW201245187A (en) Pyrazole derivatives
KR20240051861A (ko) Yap-tead 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물
HK1183480A (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842
HK1142594A (en) Piperazine and piperidine mglur5 potentiators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20081001